Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 1:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ADHD medication Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Reducing Disparities in Behavioral Health Treatment for Children in Primary Care

NCT04082234
View directory record Official record
Conditions
ADHD
Interventions
Partnering to Achieve School Success (PASS), Treatment as Usual (TAU)
Behavioral · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
5 Years to 11 Years
Enrollment
283 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 13, 2026, 1:06 PM EDT
Completed Phase 4 Interventional Results available

Impact of Strattera and Behavior Therapy on the Home and School Functioning of Children With ADHD

NCT00918567
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
atomoxetine, Behavior Modification Therapy
Drug · Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
6 Years to 12 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Sep 13, 2026, 1:06 PM EDT
Completed Phase 4 Interventional Results available

Study of Medication Patch to Treat Children Ages 6-12 With ADHD

NCT00586157
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate Transdermal System, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 12 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 15, 2012 · Synced Sep 13, 2026, 1:06 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of a Supplement on the Side Effects Associated With Stimulant Medications

NCT07380412
View directory record Official record
Conditions
ADHD, Sleep Disturbance, Brain Fog
Interventions
Stasis Daytime and Nighttime, Placebo
Dietary Supplement
Lead sponsor
Outliers, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 13, 2026, 1:06 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine

NCT06853665
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD), Autism, Autism Spectrum Disorder
Interventions
Adderall XR (mixed salts amphetamine), Placebo
Drug
Lead sponsor
Gagan Joshi
Other
Eligibility
8 Years to 18 Years
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 13, 2026, 1:06 PM EDT
Completed Not applicable Interventional Results available

Tools to Improve Medication Continuity in Adolescents With ADHD

NCT04173000
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Mehealth for ADHD software with medication continuity tools, Mehealth for ADHD software without medication continuity tools
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
11 Years to 15 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Sep 13, 2026, 1:06 PM EDT
Completed Phase 4 Interventional Results available

The BIomarker Guided (BIG) Study for Depression

NCT04181736
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Guanfacine Tablets
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 69 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Sep 13, 2026, 1:06 PM EDT
Active, not recruiting Phase 3 Interventional

Treating Parents with ADHD and Their Young Children Via Telehealth: a Hybrid Type I Effectiveness-Implementation Trial

NCT04240756
View directory record Official record
Conditions
ADHD, Parenting
Interventions
Behavioral Parent Training, Extended release mixed amphetamine salts (MAS)
Behavioral · Drug
Lead sponsor
University of Maryland, College Park
Other
Eligibility
3 Years to 65 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced Sep 13, 2026, 1:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic and Safety of Ramelteon Between Adolescents With Insomnia and Healthy Adults

NCT00914862
View directory record Official record
Conditions
Insomnia
Interventions
Ramelteon
Drug
Lead sponsor
Takeda
Industry
Eligibility
6 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Overland Park, Kansas • Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 3, 2012 · Synced Sep 13, 2026, 1:06 PM EDT
Not listed Phase 4 Interventional

Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study)

NCT00794625
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Valproate, Risperidone, Placebo, Stimulant medication, Behavioral family counseling
Drug · Behavioral
Lead sponsor
Joseph Blader
NIH
Eligibility
6 Years to 12 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Glen Oaks, New York • Stony Brook, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2012 · Synced Sep 13, 2026, 1:06 PM EDT
Completed Not applicable Interventional

Stimulant Drug Treatment of Attention-Deficit Hyperactivity Disorder (AD/HD), Inattentive Type

NCT00824317
View directory record Official record
Conditions
ADHD
Interventions
methylphenidate, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
7 Years to 13 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2009 · Synced Sep 13, 2026, 1:06 PM EDT
Completed Phase 3 Interventional

Further Studies of Attention Deficit Disorder - Residual Type (RT)

NCT00693212
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
methylphenidate, placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
21 Years to 55 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1986 – 1994
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 5, 2008 · Synced Sep 13, 2026, 1:06 PM EDT
Completed No phase listed Observational

Measuring Adherence to Medication for Depression and Attention-deficit Hyperactivity Disorder

NCT01430767
View directory record Official record
Conditions
Major Depressive Disorder, Attention-deficit Hyperactivity Disorder (ADHD)
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Sep 13, 2026, 1:06 PM EDT
Completed Not applicable Interventional Results available

Blue Wavelength Light-blocking Glasses in ADHD-Insomnia

NCT01557595
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Delayed Sleep Phase Type Circadian Rhythm Sleep Disorder
Interventions
Polarized glasses designed to filter out blue light
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 13, 2026, 1:06 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301

NCT05286762
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined, Attention-deficit Hyperactivity, Attention Deficit Hyper Activity
Interventions
CTx-1301-Dexmethylphenidate 12.5 mg (titration only), CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 37.5 mg (randomized fixed dose), Placebo
Drug
Lead sponsor
Cingulate Therapeutics
Industry
Eligibility
6 Years to 17 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
24
States / cities
Jacksonville, Florida • Maitland, Florida • Orlando, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 13, 2026, 1:06 PM EDT
Completed Phase 3 Interventional Results available

A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting

NCT02520388
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
HLD200 methylphenidate hydrochloride (MPH) Capsules, Placebo
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 12 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
21
States / cities
Newport Beach, California • Bradenton, Florida • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Sep 13, 2026, 1:06 PM EDT
Completed Phase 4 Interventional Results available

Stimulant Versus Nonstimulant Medication for Attention Deficit Hyperactivity Disorder in Children

NCT00183391
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Atomoxetine, Methylphenidate
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
6 Years to 17 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Sep 13, 2026, 1:06 PM EDT
Completed No phase listed Observational

IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents

NCT01232361
View directory record Official record
Conditions
ADHD, HIV
Interventions
Not listed
Lead sponsor
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Network
Eligibility
6 Years to 25 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
21
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Sep 13, 2026, 1:06 PM EDT
Completed Not applicable Interventional Results available

Preventing Prescription Stimulant Diversion and Medication Misuse Via a Web-Based Simulation Intervention

NCT04885166
View directory record Official record
Conditions
Prescription Drug Abuse (Not Dependent), Intentional Misuse
Interventions
Web-based placebo presentation, Web-based simulation active intervention
Other · Behavioral
Lead sponsor
Trinity College
Other
Eligibility
17 Years to 25 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Hartford, Connecticut • San Marcos, Texas • Laramie, Wyoming
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 13, 2026, 1:06 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Safety & Efficacy of d-Amphetamine Transdermal System vs Placebo in Children & Adolescents With ADHD

NCT01711021
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
d-Amphetamine Transdermal Patch, Placebo patch
Drug
Lead sponsor
Noven Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Irvine, California • Miami, Florida • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Sep 13, 2026, 1:06 PM EDT
Completed Phase 4 Interventional Results available

Interventions for Children With Attention and Reading Disorders

NCT01133847
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Reading Disabilities
Interventions
Methylphenidate, Intensive reading instruction, Parent Training, Mixed Salt Amphetamine, Atomoxetine, Guanfacine
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
7 Years to 12 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Cincinnati, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Sep 13, 2026, 1:06 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

System for Determining Ideal Drug Doses for ADHD - Stages 1 and 2

NCT03523663
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
no intervention. measure eye movement data
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
8 Years to 12 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Sep 13, 2026, 1:06 PM EDT
Completed Phase 4 Interventional

Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy

NCT00323947
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Epilepsy
Interventions
Extended Release Methylphenidate (OROS-Methylphenidate)
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years to 18 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2013 · Synced Sep 13, 2026, 1:06 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse

NCT00248092
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders, Substance-Related Disorders
Interventions
NRP104
Drug
Lead sponsor
New River Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2007 · Synced Sep 13, 2026, 1:06 PM EDT